Wu B, He X, Tang Z, Martin A, Bracher M, Guo N, Campbell K. Cost-effectiveness analysis of belimumab for the treatment of adults with active lupus nephritis in China. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA.
Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N. Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S180. doi: 10.1016/j.jval.2023.03.972
Bello N, Meyers KJ, Workman J, Hartley L, McMahon M. Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. Lupus. 2023 Mar;32(3):325-41. doi: 10.1177/09612033221147471
Bello N, Meyers KJ, Workman J, Marcano Belisario J, Cervera R. Systematic literature review and meta-analysis of venous thromboembolism events in systemic lupus erythematosus. Rheum Ther. 2023 Feb 1;10(1):7-34. doi: 10.1007/s40744-022-00513-1
Xu X, Datto C, Kwiatek J, Meyers J, Candrilli S, Mines D, Stirnadel-Farrant H. Comparison of healthcare resource utilization and costs in patients with and without Bullous Pemphigoid: a retrospective analysis of US health insurance claims data. Poster presented at the ISPOR 2022 Conference; May 18, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Anderson-Smits C, Mitchell S, Hawe E, Hartley L. Use of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy: a systematic literature review. Poster presented at the 2022 Peripheral Nerve Society (PNS) Annual Meeting; May 14, 2022. Miami, FL.
Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265
Inui K, Sato M, Esterberg E, Parikh RC, Kimura S, Torisu-Itakura H. Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis. Mod Rheumatol. 2021 Nov;31(6):1179-91. doi: 10.1080/14397595.2021.1886629
Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of Secukinumab. Dermatol Ther. 2021 Aug;11(4):1373-84. doi: 10.1007/s13555-021-00564-2
Stull K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase III clinical trials. Poster presented at the 2020 Virtual 29th European Academy of Dermatology and Venerology Congress; October 28, 2020.
Tomita T, Sato M, Esterberg E, Parikh RC, Hagimori K, Nakajo K. Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: a hospital claims database analysis. Mod Rheumatol. 2020 Jun 19;1-11. doi: 10.1080/14397595.2020.1775927
Ajmera M, Parikh R, Meyers J. Autoimmune disorders among adults with asthma: an economic outlook. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.
Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998
Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018 Jan;384(2018):96-103. doi: 10.1016/j.jns.2017.11.022
Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A. Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.
White M, Hogue S, Odom D, Cooney D, Bartsch J, Hollis K, Herrem C, Silvia S. EPIPEN4SCHOOLS® survey combined analysis: a comprehensive assessment of anaphylaxis in US schools. Presented at the 2016 AAP National Conference & Exhibition; October 22, 2016. Sacramento, CA.
White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S. Anaphylaxis in schools: results of the EPIPEN4SCHOOLS survey combined analysis. Pediatr Allergy Immunol Pulmonol. 2016 Sep;29(3):149-54. doi: 10.1089/ped.2016.0675
Hogue SL, Silvia S, Hollis K. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the NASN 2016 48th Annual Conference; June 2016. Indianapolis, IN. Previously presented at the 2016 ACAAI Conference.
Graham CN, Gunda P, Miles L, Jugl S, Palaka E, McBride D. A new cost-effectiveness framework for modeling ankylosing spondylitis treatments. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A234.
Hogue SL, Silvia S, Hollis K, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 19, 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S116. Previously presented at the 2016 ACAAI Conference.
Hogue SL, Silvia S, Hollis K, Wooddell MJ, Goss D, Odom D, Cooney D, White MV. EPIPEN4SCHOOLS® survey combined analysis: staff training and use of epinephrine auto-injectors. Poster presented at the 2016 ACAAI Conference; March 4, 2016. Los Angeles, CA.
Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016
Kandala NB, Connock M, Grove A, Sutcliffe P, Mohiuddin S, Hartley L, Court R, Cummins E, Gordon C, Clarke A. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. BMJ Open. 2013 Jul 19;3(7):pii: e002.
Candrilli SD, Davis KL, Balkrishnan R, O'Brien S. Changes in rates of sickle cell disease-related inpatient stays and associated resource use among African Americans in the United States following approval of hydroxyurea. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.
Candrilli SD, Kappelman MD, Karve SJ, Tennis PS, Andrews EB, Massie SE. Comorbidity burden among US pediatric patients with systemic lupus erythematosus and inflammatory bowel disease. Poster presented at the 2009 Pediatric Academic Societies' Annual Meeting; May 2009.